Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN sufentanil + ketamine in pediatric acute moderate-to-severe pain
2023-504023-63-00Phase 2Completed
- Sponsor
- Cessatech
- Start
- Oct 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sufentanil and ketamine in pain, sponsored by Cessatech. Primary endpoint: Analgesic efficacy (primary). Started Oct 2023; status: completed.
02
Drugs
sufentanilketamine
03
Conditions
pain
Beyond the preview
Go deeper on 2023-504023-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504023-63-00.